Trump/Putin summit, UnitedHealth and Japan’s GDP - what’s moving markets
Investing.com - Guggenheim raised its price target on Johnson & Johnson (NYSE:JNJ) stock to $167.00 from $164.00 on Thursday, while maintaining a Neutral rating on the healthcare giant.
The price target increase follows Johnson & Johnson’s strong second-quarter 2025 results, which drove shares up approximately 6.2% compared to the S&P’s 0.3% gain on the day.
Both the company’s Innovative Medicine and MedTech segments performed better than expected, marking the first time since the fourth quarter of 2023 that both divisions exceeded expectations simultaneously.
Johnson & Johnson management expects operational sales growth to be stronger in the second half of 2025 compared to the first half, with 2026 sales growth projected to surpass 2025 levels. The company also anticipates bottom-line growth to match or exceed top-line performance.
Despite the positive outlook, Guggenheim maintained its Neutral stance, citing concerns about visibility on Johnson & Johnson’s emerging Innovative Medicine pipeline needed to offset Stelara’s decline and upcoming patent expirations for Xarelto, Opsumit, and Uptravi, as well as predictability issues in the MedTech segment.
In other recent news, Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Priority Review to its New Drug Application for TAR-200, a treatment for BCG-unresponsive high-risk non-muscle invasive bladder cancer. This decision is supported by data from the Phase 2b SunRISe-1 study, which reported an 82.4% complete response rate. Meanwhile, Goldman Sachs has raised its price target for Johnson & Johnson to $185, maintaining a Buy rating, following the company’s strong second-quarter earnings report and increased full-year guidance. Stifel has also increased its price target to $165, citing an upward revision in Johnson & Johnson’s earnings per share guidance and operational revenue growth. Wolfe Research reiterated an Outperform rating with a $175 price target, highlighting Johnson & Johnson’s year-to-date outperformance and potential tariff relief. Additionally, Goldman Sachs continues to uphold its Conviction Buy rating, noting strong performance in the Innovative Medicine segment. These developments reflect the company’s strategic advancements and robust financial outlook amidst ongoing litigation challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.